Equity Overview
Price & Market Data
Price: $33.91
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $3,898,816,512
Daily Volume: 0
Performance Metrics
1 Week: 15.62%
1 Month: 13.56%
3 Months: 1.28%
6 Months: 10.56%
1 Year: 113.8%
YTD: -3.34%
Company Details
Employees: 100
Sector: Commercial services
Industry: Miscellaneous commercial services
Country: Netherlands
Details
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.